Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if prophylactic cotrimoxazole makes severe anemia
or neutropenia more common in infants exposed to maternal HIV and combination antiretroviral
therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Harvard School of Public Health Harvard School of Public Health (HSPH)
Collaborators:
Fogarty International Center of the National Institute of Health Harvard Initiative for Global Health John E. Fogarty International Center (FIC) National Institute of Allergy and Infectious Diseases (NIAID) The American Society of Tropical Medicine and Hygiene
Treatments:
Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination